ESMO 2018: Tumor Molecular Characteristics in Patients with International Metastatic Renal Cell Carcinoma Database Consortium- Good and Intermediate/Poor Risk

Munich, Germany (UroToday.com) In advanced clear cell renal cell carcinoma (ccRCC), Checkmate214 demonstrated superior response rates (RR) and progression-free survival (PFS) with ipilimumab/nivolumab (IPI/NIVO) in IMDC intermediate and poor risk patients; patients with good-risk did better with sunitinib.  Around the same time, the CABOSUN trial demonstrated similar efficacy of cabozantinib in intermediate/poor risk patients, with sunitinib being better in good risk patients. As such, cabozantinib and ipi/nivo have become standard of care first-line agents for patients with intermediate and poor risk patients – but how do we decide which agent to use? Biomarkers are desperately needed.

Prior work by the primary author (Beuselinck et al. CCR 2015 and Acta Oncologia 2017) have demonstrated that within ccRCC there are 4 molecular subtypes (1-4). ccRCC type 2 had a high angiogenic gene signature, long PFS and good response to TKI – likely corresponding to “good risk disease”. ccRCC 1 and 4, however, had intermediate and poor PFS and poor response to TKI’s.

In this study, the authors aim to study the underlying biologic mechanisms. They analyzed their ccRCC databank of patients and correlated the IMDC prognostic score at start of systemic therapy with mRNA-expression of genes involved in angiogenesis (HIF1A/2A, VEGFA, VEGFR1/2/3) and in the immunosuppressive microenvironment (PD1, PDL1/2, LAG3, CD8A, CD3G, IFNG, CXCL13) and with the molecular ccrcc1-4 classification of the primary tumor.

UroToday ESMO2018 Tumor Molecular Characteristics in Patients with International Metastatic Renal Cell Carcinoma Database Consortium

They had 162 patients in the study, of which 14% were IMDC good-risk (G-risk), 65% intermediate (I-risk) and 21% poor risk (P-risk).

The majority of G-risk pts (77%) had ccrcc2-tumors, which correlates well to the high PFS and response to TKIs. Good-risk patients were less likely to have ccrcc1- (14%) and ccrcc4-tumors (0%).

In I/P-risk patients, ccrcc2-tumors were less frequent (41%), and ccrcc1- (34%) and ccrcc4-tumors (20%) more frequent – again consistent with prior work.

mRNA expression of HIF2A, VEGFR1, -2 and -3 (angiogenesis pathway) was higher in G-risk pts compared to I/P-risk pts, correlating with a higher angiogenic profile and response to TKIs Identical expression of immune-related genes was found across all IMDC subgroups.


Presented by: Beuselinck Benoit, Prof. Dr. medical Oncologist, Leuven, Belgium

Written by: Thenappan Chandrasekar, MD, Clinical Instructor, Thomas Jefferson University, twitter: @tchandra_uromd, @TjuUrology at the 2018 European Society for Medical Oncology Congress (#ESMO18), October 19-23,  2018, Munich Germany
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe